Hypertyrosinaemia We are currently conducting research into treating nitisinone-induced hypertyrosinaemia¹ in partnership with a number of collaborators including the University of Liverpool. Nitisinone is an extremely effective treatment which reduces homogentisic...
Diagnosis The diagnosis of AKU is made upon the identification of characteristic symptoms, patient history, and clinical evaluation. Identification of elevated levels of homogentisic acid (HGA) in the urine is indicative of AKU. AKU should be suspected of all...
Treatment AKU can be treated using the drug nitisinone. Our seven year DevelopAKUre study, which concluded in 2020, illustrated nitisinone effectively halts the build of homogentisic acid (HGA) by 99%. Nitisinone received a marketing authorisation from the European...
AKU Research Bursary Award We are pleased to announce that we are launching a bursary scheme for scientific research into alkaptonuria (AKU). Designed to support early-stage researchers who are committed to advancing our understanding of AKU, successful applicants...
Information For International Patients aimAKU aimAKU is the patient support group for AKU patients and their families in Italy. Access their website here. AKU Society APAC The AKU Society of Asia-Pacific is the patient support group for AKU patients and their families...
